Drug Trial Radar · NCT00707499
A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158
Last checked: Nov 20, 2026Latest source record: Nov 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Sep 2007
Primary completion
May 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Lantheus Medical ImagingIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn the safety and biodistribution of BMS747158 in normal, healthy volunteers.
Conditions
- Healthy
Interventions
BMS747158Drug
Single dose administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dosimetry analysis following whole body imaging after resting injectionTime frame: Imaging takes place 0 - 310 minutes post injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.